Analyst Ratings For Apellis Pharmaceuticals Inc (NASDAQ:APLS)
Today, Apellis Pharmaceuticals Inc (NASDAQ:APLS) stock was downgraded by JPMorgan Chase & Co. from Overweight to Neutral.
There are 4 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Apellis Pharmaceuticals Inc (NASDAQ:APLS) is Buy with a consensus target price of $41.40 per share, a potential 208.04% upside.
Some recent analyst ratings include
- 1/23/2019-Apellis Pharmaceuticals Inc (NASDAQ:APLS) gets downgraded to Neutral by JPMorgan Chase & Co.
- 1/8/2019-Apellis Pharmaceuticals Inc (NASDAQ:APLS) has coverage initiated with a Buy rating and $40.00 price target
- 12/20/2018-Apellis Pharmaceuticals Inc (NASDAQ:APLS) had its Buy rating reiterated by Cantor Fitzgerald with a $53.00 price target
- 8/1/2018-Apellis Pharmaceuticals Inc (NASDAQ:APLS) had its Buy rating reiterated by Cowen with a $40.00 price target
- 12/4/2017-Apellis Pharmaceuticals Inc (NASDAQ:APLS) has coverage initiated with a Outperform rating
- On 9/21/2018 Morningside Venture Investment, Major Shareholder, bought 81,323 with an average share price of $19.48 per share and the total transaction amounting to $1,584,172.04.
- On 9/19/2018 Morningside Venture Investment, Major Shareholder, bought 140,000 with an average share price of $18.34 per share and the total transaction amounting to $2,567,600.00.
- On 9/14/2018 David O Watson, General Counsel, sold 15,776 with an average share price of $18.78 per share and the total transaction amounting to $296,273.28.
- On 5/24/2018 Lukas Scheibler, Insider, bought 2,935 with an average share price of $20.37 per share and the total transaction amounting to $59,785.95.
- On 11/13/2017 Global Strategic Fund I Venbio, Major Shareholder, bought 127,515 with an average share price of $14.00 per share and the total transaction amounting to $1,785,210.00.
About Apellis Pharmaceuticals Inc (NASDAQ:APLS)
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology. The company develops APL-2 for intravitreal injection that is an injection into the eye, as well as subcutaneous injection, which is an injection into the tissue under the skin. It also develops APL-9 for intravenous administration in systemic indications, which is in single ascending dose Phase I clinical trial. The company has a development agreement with Enable Injections, Inc. to develop wearable devices for subcutaneous delivery of high-volume therapeutics. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.
Recent Trading Activity for Apellis Pharmaceuticals Inc (NASDAQ:APLS)
Shares of Apellis Pharmaceuticals Inc closed the previous trading session at 13,44 −1,44 9,68 % with 205100 shares trading hands.